Provided by Tiger Trade Technology Pte. Ltd.

WUXI BIO

54.100
-2.600-4.59%
Volume:35.37M
Turnover:1.95B
Market Cap:222.68B
PE:39.82
High:57.250
Open:56.700
Low:53.800
Close:56.700
52wk High:58.000
52wk Low:28.480
Shares:4.12B
HK Float Shares:4.12B
Volume Ratio:1.66
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.359
ROE:11.38%
ROA:7.60%
PB:3.96
PE(LYR):39.82
PS:8.05

Loading ...

Movement Alert|WuXi Biologics Rises 3.24% in Regular Trading, Star Fund Manager Zhao Feng Adds Stock as New Top-10 Holding

Market Focus
·
Jul 20

Wuxi Biologics (cayman) Stock Slips 6.0% in Hong Kong

Dow Jones
·
Jul 17

Movement Alert|WuXi Biologics Falls 3.26% in Regular Trading, Trading at 37.54 HKD

Market Focus
·
Jul 17

Wuxi XDC Files HKEX Next-day Disclosure Return, Share Capital Rises by 1,121,205 Shares

Reuters
·
Jul 17

Research Monkey Prices Soar to A$20k, Supply Falls Short as CRO Industry Orders Rebound

Stock News
·
Jul 16

Wuxi Biologics (cayman) Stock Rallies 3.5% in Hong Kong

Dow Jones
·
Jul 15

Movement Alert|WuXi Biologics Rises 3.66% in Regular Trading, Life Sciences Sector Rallies as FDA Approval Momentum Persists

Market Focus
·
Jul 15

Wuxi XDC Files HKEX Next-day Disclosure Return, Share Capital Rises by 2,004,133 Shares

Reuters
·
Jul 14

Movement Alert|WuXi Biologics Declines 3.27% in Regular Trading, Trading at HK$37.0

Market Focus
·
Jul 14

Wuxi Biologics (cayman) Stock Falls 1.7% in Hong Kong

Dow Jones
·
Jul 13

WuXi Biologics (Cayman) (SEHK:2269) Wins FDA Inspection As Its Undervalued Case Builds

Simply Wall St.
·
Jul 12

TOT Biopharm Schedules Board Meeting to Review Interim Results

Reuters
·
Jul 10

Wuxi XDC Schedules Board Meeting to Review Interim Results

Reuters
·
Jul 10

Wuxi Biologics (cayman) Stock Rises 2.4% in Hong Kong

Dow Jones
·
Jul 10

Movement Alert|WuXi Biologics Rises 3.45% in Regular Trading, MFG8 Drug Substance Facility FDA Approval Continues to Boost Sentiment

Market Focus
·
Jul 10

Wuxi Biologics (cayman) Stock Rallies 3.9% in Hong Kong

Dow Jones
·
Jul 09

Wuxi Biologics' MFG8 Drug Substance Facility Secures FDA Pli Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy

THOMSON REUTERS
·
Jul 09

WUXI BIO Shares Surge Over 6% as MFG8 Facility Passes Key FDA Pre-Approval Inspection

Deep News
·
Jul 09

Wuxi Biologics’ MFG8 Drug Substance Plant Passes FDA Pre-license Inspection

Reuters
·
Jul 09

Movement Alert|WuXi Biologics Rises 3.03% in Regular Trading, Sector Rebound Combined with Sustained High-Frequency Buybacks Boost Confidence

Market Focus
·
Jul 09